ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Ann Thorac Surg 2012;93:251-258. doi:10.1016/j.athoracsur.2011.08.086
© 2012 The Society of Thoracic Surgeons

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Domenico Galetta
Piergiorgio Solli
Alessandro Borri
Francesco Petrella
Roberto Gasparri
Lorenzo Spaggiari
Right arrow Permission Requests
Google Scholar
Right arrow Articles by Galetta, D.
Right arrow Articles by Spaggiari, L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galetta, D.
Right arrow Articles by Spaggiari, L.
Related Collections
Right arrow Lung - cancer


Original Articles: General Thoracic

Bilobectomy for Lung Cancer: Analysis of Indications, Postoperative Results, and Long-Term Outcomes

Domenico Galetta, MD, PhDa,*, Piergiorgio Solli, MD, PhDa, Alessandro Borri, MDa, Francesco Petrella, MDa, Roberto Gasparri, MDa, Daniela Brambilla, MSa, Lorenzo Spaggiari, MD, PhDa,b

a Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
b University of Milan School of Medicine, Milan, Italy

Accepted for publication August 30, 2011.

* Address correspondence to Dr Galetta, Division of Thoracic Surgery, European Institute of Oncology, Via Ripamonti, 435, Milan, Italy (Email: mimgaletta{at}yahoo.com).

Presented at the Fifty-seventh Annual Meeting of the Southern Thoracic Surgical Association, Orlando, FL, Nov, 3–6, 2010.

Background: Bilobectomy for lung cancer is considered a high-risk procedure for the increased postoperative complication rate and the negative impact on survival. We analyzed the safety and the oncologic results of this procedure.

Methods: We retrospectively reviewed patients who underwent bilobectomy for lung cancer between October 1998 and August 2009. Age, gender, bilobectomy type and indication, complications, pathology, stage, and survival were analyzed.

Results: Bilobectomy was performed on 146 patients (101 men; mean age, 62 years). There were 77 upper-middle and 69 middle-lower bilobectomies. Indications were tumor extending across the fissure in 27 (18.5%) patients, endobronchial tumor in 39 (26.7%), extrinsic tumor or nodal invasion of bronchus intermedius in 66 (45.2%), and vascular invasion in 14 (9.6%). An extended resection was performed in 24 patients (16.4%). Induction therapy was performed in 43 patients (29.4%). Thirty-day mortality was 1.4% (n = 2). Overall morbidity was 47.2%. Mean chest tube persistence was 7 days (range, 6 to 46 days). Overall 5-year survival was 58%. Significance differences in survival were observed among different stages (stage I, 70%; stage II, 55%; stage III, 40%; p = 0.0003) and the N status (N0, 69%; N1, 56%; N2, 40%; p = 0.0005). Extended procedure (p = 0.0003) and superior bilobectomy (p = 0.0008) adversely influenced survival. Multivariate analysis demonstrated that an extended resection (p = 0.01), an advanced N disease (p = 0.02), and an upper-mild lobectomy (p = 0.02) adversely affected prognosis.

Conclusions: Bilobectomy is associated with a low mortality and an increased morbidity. Survival relates to disease stage and N factor. Optimal prognosis is obtained in patients with lower-middle lobectomy without extension of the resection.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2012 by The Society of Thoracic Surgeons.